WallStSmart

AbbVie Inc (ABBV)vsSeagate Technology PLC (STX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 471% more annual revenue ($62.82B vs $11.01B). STX leads profitability with a 21.6% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.61. STX earns a higher WallStSmart Score of 77/100 (B+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

STX

Strong Buy

77

out of 100

Grade: B+

Growth: 7.3Profit: 9.5Value: 5.0Quality: 4.0
Piotroski: 6/9Altman Z: 0.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-52.4%)

Margin of Safety

-52.4%

Fair Value

$146.00

Current Price

$227.23

$81.23 premium

UndervaluedFair: $146.00Overvalued

Intrinsic value data unavailable for STX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.3/10
Market CapQuality
$391.50B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
32.2%10/10

Strong operational efficiency at 32.2%

Debt/EquityHealth
-11.0210/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.618/10

Growing faster than its price suggests

Free Cash FlowQuality
$3.56B8/10

Generating 3.6B in free cash flow

STX6 strengths · Avg: 9.8/10
Market CapQuality
$230.51B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
217.2%10/10

Every $100 of equity generates 217 in profit

Operating MarginProfitability
35.7%10/10

Strong operational efficiency at 35.7%

Revenue GrowthGrowth
44.1%10/10

Revenue surging 44.1% year-over-year

EPS GrowthGrowth
108.3%10/10

Earnings expanding 108.3% YoY

Profit MarginProfitability
21.6%9/10

Keeps 22 of every $100 in revenue as profit

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
108.6x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-46.2%2/10

Earnings declined 46.2%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

STX4 concerns · Avg: 1.8/10
P/E RatioValuation
97.1x2/10

Premium valuation, high expectations priced in

Price/BookValuation
189.8x2/10

Trading at 189.8x book value

Altman Z-ScoreHealth
0.622/10

Distress zone — elevated risk

Debt/EquityHealth
3.821/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.

Bull Case : STX

The strongest argument for STX centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 21.6% and operating margin at 35.7%. Revenue growth of 44.1% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.

Bear Case : STX

The primary concerns for STX are P/E Ratio, Price/Book, Altman Z-Score. A P/E of 97.1x leaves little room for execution misses. Debt-to-equity of 3.82 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABBV profiles as a value stock while STX is a growth play — different risk/reward profiles.

STX carries more volatility with a beta of 2.08 — expect wider price swings.

STX is growing revenue faster at 44.1% — sustainability is the question.

ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.

Bottom Line

STX scores higher overall (77/100 vs 63/100), backed by strong 21.6% margins and 44.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Seagate Technology PLC

TECHNOLOGY · COMPUTER HARDWARE · USA

Seagate Technology Holdings plc, an Irish public limited company (commonly referred to as Seagate) is an American data storage company.

Want to dig deeper into these stocks?